![](https://investorshub.advfn.com/uicon/157508.png?cb=1590762401)
Thursday, January 24, 2019 6:04:47 AM
Marginally effective at best in all the small study groups done. Let them do some studies with a larger study groups (if they had the money) in the 500 patient range.
Here's the policy the FDA should adopt for junk from small companies like BIEL. Let the companies products on the market for two year period. Can't hurt if the device obviously harmless due to the small watch battery it uses.
Here's another problem problem with sports injuries. There are no two injuries exactly the same, so how can an accurate study be done? It can't! Just let the device on the market and see how consumers accept it. Either the company profits, or the company dies.
Here's another thing with the ActiPatch knee patch. BIEL shows someone jogging with it on! LOL, if one were smart one would not be jogging if their knee was injured and was painful. LOL
Everything I say and write is my opinion and my opinion only. Do your own due diligence when investing
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM